BR0206960A - Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose - Google Patents
Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilceluloseInfo
- Publication number
- BR0206960A BR0206960A BR0206960-1A BR0206960A BR0206960A BR 0206960 A BR0206960 A BR 0206960A BR 0206960 A BR0206960 A BR 0206960A BR 0206960 A BR0206960 A BR 0206960A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- hydroxypropyl methylcellulose
- methylcellulose phthalate
- oral pharmaceutical
- phthalate polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0104752.1A GB0104752D0 (en) | 2001-02-27 | 2001-02-27 | Pharmaceutical compositions |
| PCT/SE2002/000327 WO2002067904A1 (en) | 2001-02-27 | 2002-02-25 | Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0206960A true BR0206960A (pt) | 2004-03-09 |
Family
ID=9909545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0206960-1A BR0206960A (pt) | 2001-02-27 | 2002-02-25 | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040138231A1 (enExample) |
| EP (1) | EP1365746A1 (enExample) |
| JP (1) | JP2004527489A (enExample) |
| KR (1) | KR20040011469A (enExample) |
| CN (1) | CN1533268A (enExample) |
| BR (1) | BR0206960A (enExample) |
| CA (1) | CA2435815A1 (enExample) |
| GB (1) | GB0104752D0 (enExample) |
| IL (1) | IL156830A0 (enExample) |
| MX (1) | MXPA03006746A (enExample) |
| NO (1) | NO20033782L (enExample) |
| NZ (1) | NZ527080A (enExample) |
| WO (1) | WO2002067904A1 (enExample) |
| ZA (1) | ZA200305386B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| WO2004105728A2 (en) * | 2003-05-27 | 2004-12-09 | Ranbaxy Laboratories Limited | Solid dispersions of cefpodoxime proxetil and processes for their preparation |
| KR100531612B1 (ko) * | 2003-08-12 | 2005-11-28 | 경동제약 주식회사 | 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제 |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| EP2278957A2 (en) * | 2008-04-15 | 2011-02-02 | Schering Corporation | Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas |
| EP2346495B2 (en) * | 2008-10-07 | 2023-05-24 | Kudos Pharmaceuticals Limited | Pharmaceutical formulation 514 |
| US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
| CN104188893A (zh) * | 2014-08-18 | 2014-12-10 | 赵明亮 | 一种盐酸环丙沙星口服固体制剂及其制备工艺 |
| CA3038312A1 (en) | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
| CA3184054A1 (en) | 2020-06-26 | 2021-12-30 | Jacob Cole | Targeted release rifaximin compositions |
| WO2025078941A1 (en) * | 2023-10-09 | 2025-04-17 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of pirtobrutinib |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57120518A (en) * | 1981-01-19 | 1982-07-27 | Tanabe Seiyaku Co Ltd | Preparation of microcapsule |
| US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| TW212139B (enExample) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| ES2111065T5 (es) * | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| DE69428707T2 (de) * | 1993-08-20 | 2002-07-11 | Nippon Shinyaku Co., Ltd. | Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren |
| CN1133634C (zh) * | 1998-05-02 | 2004-01-07 | 阿斯特拉曾尼卡有限公司 | 抑制因子Xa的杂环衍生物 |
| JP5159012B2 (ja) * | 1999-12-23 | 2013-03-06 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | 不良溶解性の薬物に対する改良された医薬組成物 |
-
2001
- 2001-02-27 GB GBGB0104752.1A patent/GB0104752D0/en not_active Ceased
-
2002
- 2002-02-25 KR KR10-2003-7011174A patent/KR20040011469A/ko not_active Withdrawn
- 2002-02-25 NZ NZ527080A patent/NZ527080A/en unknown
- 2002-02-25 US US10/468,246 patent/US20040138231A1/en not_active Abandoned
- 2002-02-25 MX MXPA03006746A patent/MXPA03006746A/es unknown
- 2002-02-25 JP JP2002567272A patent/JP2004527489A/ja active Pending
- 2002-02-25 WO PCT/SE2002/000327 patent/WO2002067904A1/en not_active Ceased
- 2002-02-25 IL IL15683002A patent/IL156830A0/xx unknown
- 2002-02-25 BR BR0206960-1A patent/BR0206960A/pt not_active IP Right Cessation
- 2002-02-25 EP EP02700946A patent/EP1365746A1/en not_active Withdrawn
- 2002-02-25 CN CNA028056256A patent/CN1533268A/zh active Pending
- 2002-02-25 CA CA002435815A patent/CA2435815A1/en not_active Abandoned
-
2003
- 2003-07-11 ZA ZA200305386A patent/ZA200305386B/en unknown
- 2003-08-26 NO NO20033782A patent/NO20033782L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200305386B (en) | 2004-10-11 |
| NZ527080A (en) | 2005-02-25 |
| KR20040011469A (ko) | 2004-02-05 |
| GB0104752D0 (en) | 2001-04-18 |
| EP1365746A1 (en) | 2003-12-03 |
| US20040138231A1 (en) | 2004-07-15 |
| MXPA03006746A (es) | 2003-10-24 |
| JP2004527489A (ja) | 2004-09-09 |
| NO20033782D0 (no) | 2003-08-26 |
| NO20033782L (no) | 2003-08-26 |
| WO2002067904A1 (en) | 2002-09-06 |
| CA2435815A1 (en) | 2002-09-06 |
| CN1533268A (zh) | 2004-09-29 |
| IL156830A0 (en) | 2004-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE302616T1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
| ATE223232T1 (de) | Tocopherolzusammensetzungen zur abgabe von biologisch aktiven substanzen | |
| CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
| ATE270544T1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
| BR9810495A (pt) | Composição farmacêutica | |
| EE200400001A (et) | alfa-metoksütsinnamaadid, nende valmistamine ja kasutamine peroksisoomi proliferaator-aktiveeritud retseptorite moduleerimiseks ning neid sisaldavad ravimkompositsioonid | |
| DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| DE60108154D1 (de) | Pharmazeutische Zubereitungen enthaltend Clavulansäure | |
| TNSN04034A1 (en) | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof | |
| MXPA04001256A (es) | Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso. | |
| TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
| DE60209929D1 (de) | Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen | |
| EE05054B1 (et) | 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis | |
| UY27929A1 (es) | Composiciones farmaceuticas de farmacos semiordenados y polimeros | |
| BR0007294A (pt) | Formulações farmacêuticas aperfeiçoadas | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| DE60330890D1 (de) | Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung | |
| ATE476177T1 (de) | Orale zubereitungen enthaltend cladribin | |
| DE60202590D1 (de) | 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen | |
| DE69921486D1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
| SE0001916D0 (sv) | Novel formulation | |
| HRP20050787A2 (en) | Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid | |
| ATE350064T1 (de) | Pharmazeutische zusammensetzungen von rapamycines | |
| YU87501A (sh) | Farmaceutski kompleksi | |
| TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2025 DE 27/10/2009. |